Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness
12 affiliations
- 1UQ Centre for MND Research, School of Biomedical Sciences, The University of Queensland, Research Road, St Lucia, Brisbane, Queensland, 4072, Australia, 61 0414653551
- 2Ametris, Pensacola, FL, United States
- 3North Star ALS, Santa Barbara, CA, United States
- 4Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England, United Kingdom
- 5Department of Neurology & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands
- 6AGH University of Krakow, Krakow, Poland
- 7Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, MA, United States
- 8Trace Neuroscience, South San Francisco, CA, United States
- 9Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- 10Department of Life Science, Manchester Metropolitan University, Manchester, England, United Kingdom
- 11Critical Path Institute, Tucson, AZ, United States
- 12ALS Therapy Development Institute, Watertown, MA, United States
Abstract
Amyotrophic lateral sclerosis (ALS) clinical trials need outcome measures that complement established end points while capturing how people function in daily life. In this viewpoint, we draw on our collective experience in ALS research, clinical trials, digital-measure development, and regulatory science, together with published evidence, a preliminary patient survey, stakeholder discussions, and experience from multisite actigraphy studies. We argue that the field now has a substantial base of longitudinal data and candidate measures, but lacks the coordinated framework needed to compare, prioritize, and validate them across studies. We identify 4 linked priorities: adopt fit-for-purpose measures in stages and within defined contexts of use; harmonize data collection and analysis; use data to shortlist and validate measures across cohorts; and prepare actigraphy methods for trial adoption through early industry and regulatory engagement. Across these priorities, actigraphy should complement rather than replace established clinical outcomes, with its integration guided by patient relevance, ALS phenotypic heterogeneity, participant, and caregiver burden, and the intended context of use. Our central message is that progress now depends less on generating additional isolated datasets or measures than on coordinating the evaluation of existing assets, and aligning future evidence generation.
Related
- Tau positron emission tomography harmonization using the CenTauR approach: General conversion equations, relevant cut-points, and external validation.
- Cross-cohort validation of EEG biomarkers using a pre-registered three-criterion framework: a demonstration in amyotrophic lateral sclerosis
- Emotional Eating Beyond Obesity: A Transdiagnostic Conceptual Analysis of Phenotyping, Measurement, and Priorities for Clinical Validation
- Conducting actigraphy-based studies in Bangladeshi primary schools: lessons from a pilot study
- Predictors of suicide attempt in adolescents with a history of self-harm: a machine learning study combining psychosocial and actigraphy measures
BibTeX
@article{steyn2026rethinking,
title = {{Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness}},
author = {Frederik Steyn and Rakesh Pilkar and Nadia Sethi and Lori Heller and Cory Holdom and Ruben P A van Eijk and Marcin Straczkiewicz and Katherine M Burke and James D Berry and Sanjay Chandriani and Gordon Jewett and Emma Hodson-Tole and Collin Hovinga and Fernando Vieira and Christine Guo},
journal = {Journal of Medical Internet Research},
year = {2026},
month = nov,
doi = {10.2196/106677},
url = {https://doi.org/10.2196/106677},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rethinking Digital Outcome Measures for Amyotrophic Lateral Sclerosis Trials: Consensus Priorities for Actigraphy Harmonization, Validation, and Regulatory Readiness
AU - Frederik Steyn
AU - Rakesh Pilkar
AU - Nadia Sethi
AU - Lori Heller
AU - Cory Holdom
AU - Ruben P A van Eijk
AU - Marcin Straczkiewicz
AU - Katherine M Burke
AU - James D Berry
AU - Sanjay Chandriani
AU - Gordon Jewett
AU - Emma Hodson-Tole
AU - Collin Hovinga
AU - Fernando Vieira
AU - Christine Guo
PY - 2026
DA - 2026/11/12
JO - Journal of Medical Internet Research
DO - 10.2196/106677
UR - https://doi.org/10.2196/106677
AB - Amyotrophic lateral sclerosis (ALS) clinical trials need outcome measures that complement established end points while capturing how people function in daily life. In this viewpoint, we draw on our collective experience in ALS research, clinical trials, digital-measure development, and regulatory science, together with published evidence, a preliminary patient survey, stakeholder discussions, and experience from multisite actigraphy studies. We argue that the field now has a substantial base of longitudinal data and candidate measures, but lacks the coordinated framework needed to compare, prioritize, and validate them across studies. We identify 4 linked priorities: adopt fit-for-purpose measures in stages and within defined contexts of use; harmonize data collection and analysis; use data to shortlist and validate measures across cohorts; and prepare actigraphy methods for trial adoption through early industry and regulatory engagement. Across these priorities, actigraphy should complement rather than replace established clinical outcomes, with its integration guided by patient relevance, ALS phenotypic heterogeneity, participant, and caregiver burden, and the intended context of use. Our central message is that progress now depends less on generating additional isolated datasets or measures than on coordinating the evaluation of existing assets, and aligning future evidence generation.
SN - 1439-4456
SN - 1438-8871
ER -